<DOC>
	<DOCNO>NCT02573233</DOCNO>
	<brief_summary>Primary Objective : To evaluate effect dupilumab , compare placebo , airway inflammation patient persistent asthma . Secondary Objective : To assess safety , tolerability , immunogenicity dupilumab compare placebo .</brief_summary>
	<brief_title>Evaluation Dupilumab 's Effects Airway Inflammation Patients With Asthma</brief_title>
	<detailed_description>The total study duration patient approximately 29 maximum 30 week , consist screen period 5 week optional 7 additional day , treatment period 12 week , post-treatment period 12 week . Patients complete treatment period may eligible participate open-label extension study .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Mometasone Furoate</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<mesh_term>Salmeterol Xinafoate</mesh_term>
	<criteria>Inclusion criterion : Male female adult physician diagnosis persistent asthma ≥12 month . Existing treatment medium high dose inhale corticosteroid combination longacting beta agonist least 3 month stable dose ≥1 month prior Visit 1 ( Screening Visit ) . Treatment third asthma controller least 3 month stable dose ≥1 month prior Visit 1 allow . Prebronchodilator force expiratory volume ( FEV1 ) 55 85 % predict normal . Exclusion criterion : Patients &lt; 18 year &gt; 65 year . Fractional exhale nitric oxide ( FeNO ) &lt; 26 ppb Visit 1 ( Screening Visit ) . Chronic obstructive pulmonary disease lung disease ( eg , idiopathic pulmonary fibrosis , eosinophilic granulomatosis polyangiitis [ ChurgStrauss Syndrome ] ) may impair lung function . A patient experience asthma exacerbation result emergency treatment , hospitalization due asthma , treatment systemic steroid time 1 month prior Visit 1 . A patient experience upper low respiratory tract infection within 4 week prior Visit 1 . Evidence lung disease ( ) asthma . Previous smoker ( smoke history &gt; 10 packyears ) current smoker ( within 6 month prior Visit 1 ) . Comorbid disease might interfere evaluation investigational medicinal product conduct study procedure ( eg , bronchoscopy ) . Antiimmunoglobulin E ( IgE ) therapy ( omalizumab ) biologic therapy within 6 month Visit 1 . Exposure another investigative study medication within time period prior Visit 1 less 5 halflives study medication . Treatment systemic ( oral injectable ) corticosteroid within 28 day Visit 1 . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>